Earnings

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

By

Roche also announced first-quarter sales shrank 1%.

LOEs continue to buffet AstraZeneca

LOEs continue to buffet AstraZeneca

By

The drugmaker expects to return emerge from 2016 with over 5,000 fewer employees and return to growth mode in 2017.

Sanofi muddles through 2013

Sanofi muddles through 2013

By

Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Watershed year ups expectations for Biogen

Watershed year ups expectations for Biogen

By

Taken to new heights on the launch of MS blockbuster Tecfidera, the drug maker has raised its 2014 forecast.

Novartis pharma sales held steady in 2013

Novartis pharma sales held steady in 2013

By

Generics took a $2.2-billion bite out of sales, but growth products like Gilenya helped to minimize the impact.

Pfizer's Q4 fails to wow, but palbo' news may

Pfizer's Q4 fails to wow, but palbo' news may

By

The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.

Analysts put weight on BMS in oncology

Analysts put weight on BMS in oncology

By

Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.

Vivus slims down in wake of sluggish sales

Vivus slims down in wake of sluggish sales

By

The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.

Novo sales rise, company braces for change

Novo sales rise, company braces for change

By

The drug maker's vision for 2014: fighting to keep Victoza top-of-mind with a US field force of around 3,000.

AstraZeneca reveals new CFO and lagging Q3 results

AstraZeneca reveals new CFO and lagging Q3 results

By

The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.

WebMD is bringing former advertisers back on board

WebMD is bringing former advertisers back on board

By

The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.

Vertex lays off 370, focuses on cystic fibrosis

The company's hep. C drug Incivek peaked in 2011. Competition and pipeline drugs have forced the company to regroup.

Pfizer posts earnings; Street interested in what's next

Pfizer posts earnings; Street interested in what's next

By

Third-quarter earnings did not stir up analysts, who were more focused on the pipeline and Pfizer's future organizational plans.

Merck seeks way to stem sales slide

Merck seeks way to stem sales slide

By

The company says it is moving its Januvia sales pitch from defending market share to expanding it.

Roche posts sales increase

Roche posts sales increase

By

Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.

J&J posts third-quarter progress

J&J posts third-quarter progress

By

The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.

Sanofi expects Q4 growth: CEO

The CEO says Sanofi's patent-loss turnaround is coming.

Lilly primes investors for possible cuts

Lilly primes investors for possible cuts

By

Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.

Analyst gives Merck tough love

By

Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.

Eylea outduels Lucentis for physician mindshare, survey shows

Eylea outduels Lucentis for physician mindshare, survey shows

By

Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.

Mixed results underscore orphan launch hurdles

By

Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.

Dendreon lowers expectations, touts DTC effort

By

The company narrowed its second quarter loss, but said its national TV campaign is driving an uptick in consumer interest.

WebMD caps search, chooses in-house CEO Schlanger

WebMD caps search, chooses in-house CEO Schlanger

By

David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.

Santarus adds contract reps to back Uceris intro

By

This is the second addition this year and brings the company's contracted sales force to 260.

AstraZeneca, Sanofi close disappointing quarter

By

The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.

Pfizer offers timing for a split; earnings dip in Q2

By

Pfizer said 2017 is the earliest the firm could split up. Meanwhile, sales dropped 7% year-on-year.

Merck braces for revenue shortfall amid patent losses

By

Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.

BMS to put more sales oomph behind Eliquis, diabetes

BMS to put more sales oomph behind Eliquis, diabetes

By

Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.

Email Newsletters